| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RSLS | Common Stock | Sale | $2,530,053 | -388,045 | -16% | $6.52 | 2,021,297 | 16 Jun 2021 | Direct | F1, F2 |
| transaction | RSLS | Common Stock | Sale | $0 | 0 | 0% | $0.000000* | 2,021,297 | 16 Jun 2021 | See Footnote 1 | |
| transaction | RSLS | Common Stock | Sale | $582,841 | -73,591 | -3.6% | $7.92 | 1,947,706 | 16 Jun 2021 | Direct | F1, F3 |
| transaction | RSLS | Common Stock | Sale | $0 | 0 | 0% | $0.000000* | 1,947,706 | 16 Jun 2021 | See Footnote 1 | |
| transaction | RSLS | Common Stock | Sale | $426,341 | -50,040 | -2.6% | $8.52 | 1,897,666 | 16 Jun 2021 | Direct | F1, F4 |
| transaction | RSLS | Common Stock | Sale | $0 | 0 | 0% | $0.000000* | 1,897,666 | 16 Jun 2021 | See Footnote 1 | |
| transaction | RSLS | Common Stock | Sale | $6,354,033 | -1,024,844 | -54% | $6.20 | 872,822 | 17 Jun 2021 | Direct | F1, F5 |
| transaction | RSLS | Common Stock | Sale | $0 | 0 | 0% | $0.000000* | 872,822 | 17 Jun 2021 | See Footnote 1 | |
| transaction | RSLS | Common Stock | Sale | $580,140 | -81,366 | -9.3% | $7.13 | 791,456 | 17 Jun 2021 | Direct | F1, F6 |
| transaction | RSLS | Common Stock | Sale | $0 | 0 | 0% | $0.000000* | 791,456 | 17 Jun 2021 | See Footnote 1 | |
| transaction | RSLS | Common Stock | Sale | $3,756,995 | -685,583 | -87% | $5.48 | 105,873 | 18 Jun 2021 | Direct | F1, F7 |
| transaction | RSLS | Common Stock | Sale | $0 | 0 | 0% | $0.000000* | 105,873 | 18 Jun 2021 | See Footnote 1 | F8 |
| Id | Content |
|---|---|
| F1 | The reported securities (the "Shares") of ReShape Lifesciences Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and together with Armistice Capital, the "Reporting Persons"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| F2 | This constitutes the weighted average purchase price. The prices range from $5.96 to $6.86. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price. |
| F3 | This constitutes the weighted average purchase price. The prices range from $7.30 to $8.06. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price. |
| F4 | This constitutes the weighted average purchase price. The prices range from $8.46 to $8.54. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price. |
| F5 | This constitutes the weighted average purchase price. The prices range from $5.86 to $6.84. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price. |
| F6 | This constitutes the weighted average purchase price. The prices range from $6.91 to $7.51. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price. |
| F7 | This constitutes the weighted average purchase price. The prices range from $5.30 to $5.86. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price. |
| F8 | Additionally, the Reporting Persons no longer have beneficial ownership of 13,333 Shares as a result of the settlement of a transaction made prior to the reporting period. Accordingly, the Reporting Persons have beneficial ownership of 92,540 Shares. |